Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases with high unmet medical needs.
We strive to address serious unmet medical needs, with the ambition to bring safe, effective therapies to market. We believe that diseases require solutions mastering their complexity by combining therapeutics in a synergistic/additive way.
We are working hard to finalize the clinical development of PXT3003 in Charcot-Marie-Tooth disease type 1A (CMT1A), and bring it to market as soon as possible through an agreement with a pharmaceutical company.
PXT3003, Pharnext's most advanced drug candidate, is in development for Charcot-Marie-Tooth disease type 1A (CMT1A), a rare, debilitating, inherited peripheral neuropathy that affects hundreds of thousands of patients worldwide on a daily basis. PXT3003 was discovered using Pharnext's proprietary R&D approach (Pleotherapy™). An international pivotal Phase III study of PXT3003, the PREMIER trial, enrolling 387 CMT1A patients was completed in August 2023.
Pharnext is a limited partnership with shares (S.C.A.). Pharnext Développement, a company controlled and managed by Neovacs, is its general partner and manager
Explore our history since inception in 2007